Quality & Compliance For Continuous Improvement

Pharmaceutical Quality; GxP Training, Consulting and Auditing Services

Essential Simplification Resources

Have A Question? Get In Touch

Like NSF, you recognize the importance and benefits of simplifying pharmaceutical operations. Take advantage of these resources including a self-assessment questionnaire to help you move from complex to simple. Make sure to share with your colleagues.

For more information on our services including auditing, consultancy, quality systems, regulatory guidance and training, contact pharmamail@nsf.org or visit www.nsfpharma.org

Stay in touch - follow us on




White Paper: Are You Facing a Complexity Crisis?

Webinar: Implementing a Simplification Strategy

Video: How to Jumpstart Your Pharma Business by Simplifying Processes

Video: Fix SOP Complexity

Are You Facing a Complexity Crisis?

Martin Lush explains the costs of over-complexity and the true root causes. It also includes a self-assessment questionnaire for you to discuss at your next team meeting.

>> Read the White Paper 

Implementing a Simplification Strategy

This webinar from Jim Morris reviews three essential simplification strategies that site leadership and unit operations managers can pursue.

>> Watch the Webinar 

How to Jumpstart Your Pharma Business by Simplifying Processes

Making processes simple underpins GMP compliance as complexity is the catalyst for error and deviation. John Johnson shares how we use simple processes and a course toolkit to enable your team to begin the process of refinement, clarification and error proofing.

>> Watch the Video 

Fix SOP Complexity

In this short video, Martin gives his insight into how much detail we should put in a SOP to avoid overload, explaining what you should leave in and what to take out.

>> Watch the Video 

A Beginner’s Guide To Quality Risk Management (QRM)  

The pharmaceutical industry approach to assessing and controlling quality risks has largely been empirical. This is often fine but in more complex or hazardous situations, the pharmaceutical industry could benefit from a number of very helpful tools and techniques. 

> > Discover more

SIGN UP FOR YOUR COMPLIMENTARY JOURNAL AND MONTHLY E-JOURNAL – VISIT OUR WEBSITE

Go to article: Home | The deep dive for new drugsGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Hapa Company InsightGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Owen MumfordGo to article: The pharma industry briefingGo to article: Capsugel Company InsightGo to article: Swiss WorldCargoGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Underwater forests and the search for natures’ next drug treasure troveGo to article: Barc Lab Go to article: BEAGo to article: Developing drugs for NASH: the race to market Go to article: SmartCAE Company InsightGo to article: SmartCAEGo to article: Zulresso: the world’s first post-partum depression drugGo to article: EcocoolGo to article: Moehs Iberica SLGo to article: Predicting drug flops with AIGo to article: Abiogen PharmaGo to article: LaudaGo to article: Proteomics and the promise of ‘enriching’ clinical trials Go to article: Lubrizol Life SciencesGo to article: SkycellGo to article: EventsGo to article: TemptimeGo to article: Next issueGo to article: Pfanstiehl Company InsightGo to article: Pfanstiehl